SHANGHAI, June 16, 2025 — Med-Fine Capital, a VC firm focused on investing in early-stage healthcare innovation in China, has announced successful close of its second USD fund. The fund will continue investing in cutting-edge biotech startups and supporting next-gen healthcare related technologies.

Investor Confidence Despite Market Challenges

This successful fundraising comes at a pivotal moment, as China’s biotech investment market undergoes a period of adjustment. Jack Zhou, Managing Partner of Med-Fine Capital, stated, “In the current environment, the continued trust and support from our investors are particularly valuable. It is not only a recognition of our past performance and professional capabilities, but also a strong endorsement of our commitment to Med-Fine’s global development strategy.”

Med-Fine Capital remains optimistic about the future:

1.  China’s Rising Innovation Strength: From 2015 to 2024, the number of innovative drugs from China receiving first-time global approval increased from 3 to 39, a 12-fold rise, elevating China from the 3^rd to 2^nd place worldwide. Simultaneously, Chinese biotech companies have accelerated global expansion through cross-border BD transactions, reaching a total transaction value of USD 63.5 billion in 2024 (up 22.59% YoY), with 24 mega-deals (over USD 1 billion each) totaling USD 43 billion, nearly 20% of the global total.

2.  Rebound of the Hong Kong Capital Market: In May 2025, IPO proceeds in the Hong Kong stock market reached HKD 55.8 billion, the highest since March 2021. Year-to-date fundraising has reached HKD 77.4 billion, nearly 90% of the 2024 full-year total. The Hang Seng Tech Index rose by 14.9%, significantly outperforming other major global markets.

3.  Exceptional Investment Capability: The Med-Fine Capital team combines deep industry knowledge, a strong global network, and proven investment capabilities.

A Decade of Focus on Early-Stage Innovation

In the past decade, Med-Fine Capital has consistently focused on the Chinese biotech innovation ecosystem, guided by its investment philosophy of discovering early-stage opportunities and helping them grow. The firm has invested in more than 60 innovative startups so far. This newly raised fund is Med-Fine’s second USD fund, marking its establishment and steady growth in the USD investment market. LPs include global renowned FOF, Hong Kong financial institutions, Singaporean family offices, and corporations in the healthcare sector.

Backing Startups with a Global Edge

“Med-Fine Capital’s investment team possesses strong industry expertise and connections, in addition to a wealth of global experience and perspective,” said Dr. Vince Deng, Partner and Head of Biotech Investment at Med-Fine Capital. “Our focus areas include oncology, autoimmune, metabolic and CNS diseases, where we invest in globally competitive and differentiated innovation. We actively support promising Chinese biotech companies to go global, helping them in all important aspects including R&D, clinical development, and regulatory affairs during their global expansion.”

Med-Fine Capital’s approach is not only about early and precise investment. It emphasizes on deep and hands-on support to entrepreneurs to achieve exceptional return. Staying true to a “begin with the end in mind” philosophy, the firm works backward from market demand and exit possibilities to shape company development. “Med-Fine pays special attention to co-founding new ventures with serial entrepreneurs and selecting highly promising directions and assets in the right time and fashion, to reduce investment risk and create maximum return. We have already co-founded and invested in several highly promising biotech companies through the above-mentioned investment philosophy and approach in this USD fund, including Allink Biotherapeutics and VelaVigo. Most of them have already secured one or more arounds of follow-on funding led by top-tier investors. These outcomes strengthen our confidence and encourage us to keep doing what we have done again and again,” added Dr. Vince Deng.

Long-Term Partners, Global Vision

Mr. Jack Zhou emphasizes, “Med-Fine Capital is dedicated to investing in globally competitive pipeline assets. We are not just capital providers but aim to be long-term strategic partners to our portfolio companies. Our goal is to build a research-driven investment system rooted in clinical value and technological innovation, with global market value in mind and meeting unmet medical needs as the end game. We continuously strengthen our core competencies in cross-border resource integration and cross market cycle value investment to help patients globally living a better life.”

About Med-Fine Capital

Med-Fine Capital specializes in investment in healthcare and life sciences. The management team boasts a global perspective, deep industry expertise, extensive resources, and professional investment experience. Med-Fine manages several RMB and USD funds, focusing on early-stage value discovery in biotech, device, diagnostics, digital health and healthcare services. To date, Med-Fine has invested in more than 60 companies, including Mabworks, Eccogene, Zion, LYNK, Pharma Legacy, MagAssist, Alebund, Allorion, ImmVira, Degron, Allink and Castalysis.

SOURCE Med-Fine Capital

$130 million in new funding will fuel investment in JunieAI: enterprise-grade AI for private markets GPs

SAN FRANCISCO, June 16, 2025 — Juniper Square, the pioneer of connected fund software and services for private markets, today announced it closed its Series D round and secured $130 million in new funding led by Ribbit Capital, with significant strategic investment from Fifth Wall, and additional participation from Redpoint Ventures, HighSage Ventures, Blue Owl Capital and others.

Juniper Square will use the capital to accelerate investment in JunieAI—the first enterprise-grade AI built specifically for the needs of private markets GPs. JunieAI combines the power of modern large language models (LLMs) with critical enabling components—Juniper Square’s fund system of record for GPs and LPs, a scaled data model, comprehensive workflows coupled with managed services, industry integrations, and robust measures for security, control, and permissioning—to help GPs move faster, work smarter, and operate more efficiently.

As an agentic AI platform, JunieAI provides:

• Agents supporting the work of investor relations, fund administration, portfolio management, and investment decisions
• Model-agnostic orchestration across agents, tools, workflows, and systems
• Precision tools for the accuracy demands of accounting and reporting, fused with the ease of use and power of generative AI
• Secure, enterprise-grade permissioning and control
• Deep domain expertise in private markets
• AI workflows wrapped with full service solutions
• Unified structured and unstructured data—including from emails and documents
• Seamless integration with existing GP tools
• Fine-grained agent governance, empowering GPs to define how AI agents behave, respond, and defer across use cases

“The private markets are undergoing a once-in-a-generation transformation driven by two tsunamis of change: the rise of the retail investor and the breakthrough potential of AI,” says Alex Robinson, CEO and Co-Founder at Juniper Square. “Our mission is to equip GPs with the technology and services they need to thrive in this new era. With JunieAI, we’re helping our customers stay ahead—turning disruption into opportunity across every facet of work inside of the modern GP.”

“Juniper Square is uniquely positioned to lead the private markets into the AI era,” says Nick Shalek, General Partner at Ribbit Capital. “Few companies have the combination of enterprise-grade trust, enabling infrastructure, deep domain expertise, and structured data at scale that Juniper Square brings to bear. With JunieAI, they’re harnessing these strengths to build AI solutions that are purpose-built for private markets—not just bolted on. We’re thrilled to support Juniper Square as it sets the standard for how this industry will evolve.”

This fundraise follows a period of rapid growth for Juniper Square including >100% 3-year CAGR in its fund administration business, which today manages over 2,000 fund entities globally across an extensive range of strategies and complex fund structures. Growth has been especially strong in the private equity and venture capital verticals, which now represent four of the five largest customers by revenue. In May, Juniper Square expanded into Luxembourg, unlocking integrated fund administration and efficient cross-border operations for private markets GPs at a global scale.

“Juniper Square stands out as a frontrunner to lead the private markets as the world moves toward an AI-driven future,” says Jay Maher, Global Chief Operating Officer at H.I.G. Capital. “Juniper Square’s focus on AI innovation will deliver transformative benefits across the industry—empowering organizations to better serve investors and drive long-term growth.”

Over the past decade, Juniper Square has built the connected infrastructure that powers private markets, helping make the industry more efficient, transparent, and accessible. With retail investors reshaping the landscape and the market on track to exceed $60 trillion within a decade, GPs need innovations like JunieAI to keep pace and capture new opportunities.

We invite you to join Alex Robinson, CEO and Co-Founder, and Brandon Rembe, Chief Solutions Officer, for a Virtual Keynote on June 23 at 9:00 a.m. PT where they’ll share more about JunieAI and Juniper Square’s vision for private markets AI innovation – register here.

More information about Juniper Square and JunieAI can be found here.

About Juniper Square
Juniper Square is transforming the private markets investing experience with a full range of modern, connected fund software and services. More than 2,000 private markets GPs rely on Juniper Square to support their fundraising, reporting, fund administration, treasury, compliance, and business intelligence needs across more than 40,000 funds, 600,000 LP accounts, and $1 trillion of LP capital.

SOURCE Juniper Square

NEW YORK, June 16, 2025 — In a $185 billion U.S. apparel e-commerce industry saturated with choice and friction, Alta is crafting a brand new AI-native shopping experience by empowering shoppers with a personalized styling companion.

Alta announced today it has raised $11 million in seed funding to build the next generation of personal shopping and styling—powered by AI.

The round was led by Menlo Ventures with participation from Aglaé Ventures (an investment firm  backed by the Arnault family), Benchstrength Ventures, Conviction, Phenomenal Ventures, and a notable group of celebrity stylists, consumer tech founders, and AI experts, including Tony Xu, Karlie Kloss, Jasmine Tookes, Meredith Koop, Keltie Knight, Gabriel Whaley, Zita D’Hauteville, Kelvin Beachum Jr., Amjad Masad, Jenny Fleiss, and Manish Chandra. Menlo Ventures Partner Amy Wu is joining the board.

Alta’s core product is an AI stylist and personal shopper that creates shopping and outfit recommendations based on a user’s closet, lifestyle, budget, occasion, and weather. The app leverages over a dozen proprietary multimodal generative AI models, all trained in-house on fashion data. In addition to personalized outfit curations and shopping suggestions, users can try-on recommended outfits on their virtual avatar—including mixing and matching shoppable items with their own closet items. Alta’s virtual dressing room offers users an immersive and novel retail experience.

“We built Alta to make personal style effortless and fun—with an AI that truly understands you,” said founder Jenny Wang. More recently, the Council of Fashion Designers of America (the CFDA) announced a partnership with Alta.

“For years, personalized styling was a luxury reserved for the rarest occasions. Alta is breaking that mold with AI models that can decode fashion and understand personal taste at scale,” said Amy Wu, Partner at Menlo Ventures. “We were looking to work with a founder who could bridge deep technical expertise with an intuitive grasp of fashion and consumer behavior. Jenny Wang is exactly that. We’re thrilled to back her and join Alta’s journey to reimagine how people shop and dress.”

Alta’s mission is simple: to help everyone look and feel their best. The funding will accelerate Alta’s product development, expand its AI capabilities, and grow its team across engineering and operations.  For more information, visit altadaily.com, follow @alta on Instagram, or download the Alta app from the App Store.

For Media Inquiries:
[email protected]

SOURCE Alta Daily

Former Head of Health investments at Leaps by Bayer brings extensive biomedical innovation and venture capital experience to help catalyze impact-driven growth for the T1D community

The latest in a string of strategic hires signifying a new chapter for the Fund aimed at higher-conviction investments for greater mission impact

BOSTON, June 16, 2025 — The T1D Fund: A Breakthrough T1D Venture, LLC, an impact investment fund focused on accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes (T1D), today announced the appointment of Lucio Iannone, Ph.D., as its new Managing Director starting the beginning of August. With a dual background as biopharma investor and scientist, Iannone will draw upon his successful track record in dealmaking and pipeline development to help drive the Fund’s impact investment strategy, including aiding in the establishment of deal flow, fine-tuning optimal investment approaches, and providing meaningful portfolio company support. 

“Lucio’s appointment marks a pivotal moment for the T1D Fund, as we welcome a highly esteemed investment veteran to our ranks,” said Elizabeth Mily, CEO of the T1D Fund. “He will play a crucial role as we pursue the next wave of groundbreaking treatment within T1D, ensuring our dollars have a greater impact by accelerating high-potential programs and catalyzing new opportunities that are on the precipice of breakthroughs. His background in leading the generation and execution for more than 25 deals, combined with his scientific expertise, uniquely positions him to identify and support innovative companies pursuing potential cures. Building a world-class investment team to deploy in our mission of broadening industry efforts towards T1D is one of my top priorities as CEO, and Lucio’s hire is a key step toward achieving that goal.”

Iannone joins the Fund after serving as Head of Health Investments USA for Leaps by Bayer, the strategic investment arm of Bayer AG. At Leaps, he led and mentored the global investment team, driving strategic and deal execution, overseeing more than 25 biomedical investments and directing assets under management exceeding $1 billion. With expertise in oncology, autoimmune disease, cell and gene therapies, and chronic conditions, he has a deep understanding of scientific, clinical, and commercial dynamics that will directly benefit the Fund’s mission. Iannone earned his Ph.D. in Medicine at Imperial College of London, and has served on the boards of innovative companies such as Mozart Therapeutics, eGenesis Biosciences, Immunitas Therapeutics, and more.

“The T1D therapeutic landscape is ripe for innovation, and I’m eager to join the Fund’s efforts to identify, support, and direct funding to companies with curative potential,” said Iannone. “Together with this dynamic team and our network of partners, we will execute an expansive strategy to further elevate groundbreaking scientific discoveries and accelerate therapies that can transform the lives of individuals with T1D.”

Iannone’s hiring is the latest in a string of strategic appointments by the Fund, signaling a new chapter of impact investing. This infusion of expertise will help strengthen the Fund’s ability to serve as a preferred investor and partner, yielding greater program advancement, significant investment in T1D, and an amplified mission impact—further solidifying its position as the leading catalyst for the development of T1D cure-oriented therapies.

About the T1D Fund: A Breakthrough T1D Venture, LLC
Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions. Learn more at t1dfund.org. Follow the T1D Fund on Linkedin.

Media Contact
Lia Dangelico
[email protected]
540-303-0180 

SOURCE The T1D Fund

SALT LAKE CITY, June 16, 2025 — Lumion, the company building the most comprehensive operating system for career and trade schools, today announced it has raised a total of $10.7 million in seed funding led by TTV capital with recent participation from Tusk Venture Partners. The round also includes prior support from TTV Capital, CreativeCo Capital, Nine Four Ventures, Innovating Capital, and the State of Wyoming.

The funding comes amid a pivotal moment for the U.S. workforce. As the country faces a critical skilled labor shortage, enrollment growth in trade and technical programs is outpacing that of four-year colleges. Lumion is emerging as the infrastructure layer that enables schools to meet that demand, streamlining student acquisition, operations, and outcomes from end to end.

“Trade schools have been stuck managing mission-critical processes across spreadsheets, disconnected CRMs, and legacy student information systems (SISs),” said Joshua Hagani, CEO of Lumion. “We’ve built the ultimate platform to unify the full student experience from lead capture all the way through alumni tracking.”

Originally focused on student financing, Lumion has evolved into an All-in-one SaaS platform enabling trade and technical schools to grow efficiently and serve more students. Over the last year, the company has tripled its revenue, customer base and team, supporting over 100,000 students across 260+ partner schools in more than 29 industries.

The new Lumion Platform includes three major product lines:

• Enrollment: Schools can now generate and manage prospective student leads from their own website, funneling them into a centralized enrollment flow with applications, communication, scheduling and onboarding capabilities.
• Payments: Once a lead is captured and nurtured, students are guided through all available payment options including upfront payment, a lender marketplace, and school-administered payment plans ensuring increased enrollment, retention, and collection. Lumion handles all collections and servicing on behalf of schools.
• Full-Service SIS Capabilities: Lumion provides centralized comprehensive reporting of all student activities and interactions, bringing clarity and insights to school operators.

Lumion brought in Tusk Venture Partners to top off its seed round due to surplus investor demand in late 2024, accelerating market expansion and continuing product innovation.

To date, Lumion has:

• Processed over 140,000 tuition payments
• Enabled 1,690 school administrators
• Delivered an estimated $20 billion in human capital impact
• Grown to a 35-person team headquartered in Salt Lake City

With government policy tailwinds behind workforce development and a broken traditional higher education model, Lumion is the operating system of choice for trade & technical schools.

About Lumion
Lumion is the all-in-one platform for trade and technical schools, streamlining the full student lifecycle from lead generation and tuition payments to enrollment, reporting, and alumni tracking. Headquartered in Salt Lake City, Lumion is building the infrastructure for the future of skilled education. Learn more at joinlumion.com.

SOURCE Lumion

Highlights:

• Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.
• Update on NASDAQ Compliance: Klotho believes it now exceeds the stockholders’ equity thresholds required to remain in compliance with NASDAQ listing requirements.
• Zero Debt: Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.

NEW YORK, June 16, 2025 — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq’s stockholders’ equity requirement requirements outlined in its Nasdaq compliance plan.

In addition, the Company utilized  $3.1 million of the funds raised to extinguish all outstanding debt, resulting in a debt-free balance sheet.

About Klotho Neurosciences, Inc. 
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using an important human protein derived from the Company’s patented form of the “anti-aging” human Klotho gene (s-KL) and its novel promoter and delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease. The company’s current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Investor Contact and Corporate Communications – Jeffrey LeBlanc, CFO
[email protected]

Website: www.klothoneuro.com

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

SOURCE Klotho Neurosciences, Inc.

Performance Brokerage Services, the leader in dealership buy-sell activity, announces the sale of Palmdale Kia in California from Top-40 dealership group, Nouri/Shaver Automotive Group to Trust Auto Group

IRVINE, Calif., June 16, 2025 — Performance Brokerage Services, North America’s highest volume dealership brokerage firm, is pleased to announce the sale of Palmdale Kia in California from Top-40 dealership group, Nouri/Shaver Automotive Group to Trust Auto Group.

Nouri/Shaver Automotive Group is led by Co-Owners Bob Nouri and Pete Shaver, along with CEO Armina Mgerian. The group operates 16 franchised dealerships in California and Oregon. Nouri/Shaver Automotive Group ranks #40 on the Automotive News Top 150 Dealership Groups based on new-vehicle sales in 2024, generating over $2 billion in revenue, and employing more than 2,000 individuals.

After the sale, Bob Nouri shared, “I’m incredibly thankful for Jason Stopnitzky of Performance Brokerage Services’ pivotal role in selling one of our dealerships, which wasn’t even listed for sale. His integrity, marked by unwavering honesty, transparency, and a steadfast commitment to doing what’s right, set him apart in every interaction. He navigated the process with professionalism and genuine care, making it not only seamless but also a true pleasure. In an industry with many great people, Jason’s exceptional character and principled approach make him a rare gem. It’s an honor to work with someone of such high caliber. Thank you, Jason, for your remarkable impact!”

Over the last 5 years, Performance Brokerage Services has advised on the sale of nearly 400 dealerships, making it the highest volume dealership brokerage firm in North America. Jason Stopnitzky, Co-Founder, and Jesse Stopnitzky, Co-Owner of Performance Brokerage Services were the exclusive sell-side advisors for this transaction.

Jason Stopnitzky commented, “Bob Nouri, Pete Shaver, and Armina Mgerian have my deepest gratitude for their unwavering trust and collaboration. This marks our fifth transaction together. After 27 years in the business, I’ve been a part of hundreds of transactions and have worked alongside many dealers. The team they’ve built sets the gold standard in the industry I’ve dedicated my life to. The way they treat their employees, customers, and OEMs across 16 dealerships sets an incredibly high bar, and it’s amazing how they continue to strive for excellence while managing over 2,000 employees. I feel truly blessed and fortunate to be part of their inner circle. As always, I’m thankful for the chance to serve, and I always give my all for the Nouri/Shaver Automotive Group.”

Jason continued, “I’m also grateful to Edgar Castellanos and Trust Auto Group for their trust and partnership in acquiring Palmdale Kia. It’s been a pleasure to witness how both parties worked together seamlessly throughout the process, and I’m confident that the legacy of Palmdale Kia will continue under Trust Auto Group’s stewardship. The collaboration between both sides was a testament to what can be achieved when great people come together to achieve a common goal.”

Trust Auto Group is a locally owned and operated dealership group with five locations across Costa Mesa, Lancaster, and Palmdale, California. The group represents brands including Honda, Subaru, Kia, and Lotus.

President of Trust Auto Group, Edgar Castellanos commented, “It’s been an absolute pleasure working with Jason Stopnitzky of Performance Brokerage Services, from the initial call to the conclusion of our purchase. Every step of the way, he handled the process with urgency and care. His attention to detail and meticulous oversight of the entire process made the acquisition stress-free. Looking forward to many more years of working with him and his team.”

Nouri/Shaver Automotive Group was represented by Monica Hoenshell of Calvert Law Firm in Oklahoma City, Oklahoma.

Palmdale Kia will be renamed Trust Kia of Palmdale and will remain at its current location at 438 Auto Vista Drive in Palmdale, California.

About Performance Brokerage Services

Performance Brokerage Services, Inc. is North America’s highest volume dealership brokerage firm, specializing in buy-sell activity for automotive, RV, commercial truck, powersports, and equipment dealerships.

With over 30 years of experience, 900 dealerships sold, and a 90% closing rate, the company’s reputation is unmatched and governed by the utmost ethical conduct and integrity.

The company offers a unique approach by providing complimentary estimates of value with no upfront fees or retainer, no reimbursement of costs, and paid a success fee only after the transaction closes.

Headquartered in Irvine, California and supported by 12 regional offices across the United States and Canada, clients benefit from national exposure with local representation.

As trusted and respected experts in the field, the company utilizes an extensive network of industry related attorneys, accountants, hundreds of registered buyers, and longstanding relationships with various vehicle manufacturers.

For more information about the services offered by Performance Brokerage Services, visit https://performancebrokerageservices.com. 

Media Contact: 
Jesse Stopnitzky, Co-Owner
(949) 309-2851
[email protected]

SOURCE Performance Brokerage Services, Inc.

• Pioneering the Future of Surgical Care in Response to Rising Demand

TOKYO, June 15, 2025 — SDP Japan, Inc. (Shibuya-ku, Tokyo; CEO: Kazuhiko Nagayo), announced today that the Company has successfully raised approximately JPY 4.5 billion (equivalent to USD 31 million) through a Series D equity financing round, alongside secondary transaction, debt financing and asset-based funding. The equity round was led by Japan Post Investment and included participation from seven institutional investors.

Background and Future Outlook

Japan’s super-aging society continues to fuel steady growth in the healthcare sector, particularly in the fields of orthopedics and cardiovascular — two core areas of focus for SDP Japan. Surgical procedures in these specialties are increasing at 5–8% per annum, with demand projected to grow through 2050, according to research by Yano Research Institute.

Despite growing need, the surgical care sector faces systemic challenges: surgeons often lack access to adequate infrastructure and support, while patients continue to struggle with finding reliable specialists — often by chance — highlighting persistent disparities in access to information and care.

SDP Japan is redefining the surgical care model by building integrated platforms where physicians can focus purely on their expertise, and patients are guided seamlessly toward optimal treatments. With a unique position at the intersection of patient marketing, facility production, and healthcare operations management, the Company has expanded the footprint of surgery-focused medical institutions — primarily in urban areas — and is now poised to scale its next-generation model nationwide.

This funding round will further strengthen SDP Japan’s growth platform and enable the rollout of advanced surgical care models to underserved regions. The Company is committed to rebuilding medical infrastructure in regional cities through close collaboration with stakeholders across the healthcare ecosystem, aiming to establish a sustainable and equitable healthcare system.

With the agility and execution power of a startup, SDP Japan aspires to be a transformative force in the Japanese healthcare industry.

About SDP Japan

SDP Japan, Inc. is a healthcare startup with a mission to ‘deliver joy and inspiration through advanced surgical care.’ The Company supports the nationwide development of specialty surgical institutions in orthopedics and cardiovascular. SDP Japan offers a wide range of services to its partner medical institutions, including patient acquisition (marketing), supply procurement, real estate and medical equipment sourcing, and administrative support — delivering innovative solutions across the surgical care spectrum.

Since its founding in 2014, SDP Japan has helped produce seven surgery-focused institutions in the Tokyo metropolitan area. In 2024, its supported facilities performed over 3,000 surgeries, bringing the cumulative total to approximately 14,000. Those institutions rank third in Tokyo for both arrhythmia and hip joint replacement surgeries, based on the number of procedures performed (source: Shukan Asahi Mook, “Best Hospitals for Surgery 2024”).

Internationally, outpatient surgical centers are widely adopted in the form of ASCs (Ambulatory Surgical Centers) or HOPDs (Hospital Outpatient Departments), driven by robust patient outcome data. SDP Japan aims to support the establishment of a Japanese version of the ASC platform tailored to Japan’s public insurance system, contributing to the realignment of acute cares.

At the heart of our mission is the desire to deliver life-changing outcomes for patients and their families through the hands of exceptional surgeons.

Message from the CEO, Kazuhiko Nagayo

We are pleased to announce the successful completion of a JPY 4.5 billion funding round. I would like to express my sincere gratitude to our investors and supporters. At SDP Japan, we have relentlessly pursued a healthcare environment where physicians can thrive and patients can access the best possible care. Today, we support more than 3,000 surgeries annually and are committed to expanding this model to regional areas, eliminating disparities across the nation.

People are at the core of our growth. I look forward to working with mission-driven individuals who share our passion and expertise.

List of Series D Investors (in no particular order)

Existing Investors:

• Eight Roads Ventures Japan
• Globis Capital Partners

New Investors:

• Japan Post Investment (Lead Investor)
• T&D Innovation Fund / Spiral Innovation Partners
• Sumitomo Mitsui Trust Bank
• Japan Co-Invest No. 4 Fund / Sumitomo Mitsui Trust Investment
• Toda Corporation

List of Lenders (in no particular order)

• Resona Bank
• Shizuoka Bank
• SBI Shinsei Bank

Comments from New Investors

• Japan Post Investment (Lead Investor): Kei Mizukami, Executive Vice President and CIO

SDP Japan is creating an environment where surgeons can fully focus on their procedures, enabling patients to receive high-quality surgical care efficiently and safely. At the same time, the Company contributes to improving working conditions and career development opportunities for physicians. We view this initiative as one that will raise the overall standard of surgical care in Japan and improve public health outcomes, making it a compelling opportunity for impact investment. We look forward to supporting SDP Japan’s medium- to long-term growth as it partners with medical institutions across the country.

• Sumitomo Mitsui Trust Bank: Kazuya Yoneda, Head of Impact Equity Investment Department

We highly value SDP Japan Inc. as a platform company that provides unique support services for the establishment and operation of surgery-focused hospitals and clinics. Their ability to simultaneously enhance efficiency and improve the quality of medical care is particularly commendable. At our bank, we aim to support initiatives and challenges that address social issues through financial means. Through this investment, we strive to contribute to the improvement of well-being for a broad and inclusive range of people, including future generations.

• T&D Innovation Fund (managed by Spiral Innovation Partners): Kazuhiro Kamata and Yuqing Wei 

We believe that the nationwide expansion of specialized surgical medical institutions supported by SDP Japan will contribute significantly to the advancement of Japan’s healthcare system. The T&D Innovation Fund actively invests in startups in the healthcare, pet care, and insurtech sectors, and we are fully committed to supporting the growth of SDP Japan going forward.

• Japan Co-Invest IV Investment / Sumitomo Mitsui Trust Investment: David Su, Director of Investments

We saw a unique opportunity to align strong investment returns with meaningful social impact by supporting SDP Japan in expanding its network of surgery-specialized medical facilities nationwide. Similar models have been successfully evolved in the U.S. since the 1970s, contributing to reduced healthcare costs and improved access to advanced care. We are excited to back SDP Japan as it builds an innovative medical infrastructure that truly reflects the commitment of physicians and the needs of patients. We look forward to continuing our support beyond the investment itself.

• Toda Corporation: Masato Kudo, General Manager, Innovation Promotion Division

Toda Corporation has invested in SDP Japan with the goal of advancing the medical industry and addressing key social challenges. In response to the growing number of surgeries and structural issues in the healthcare sector, SDP Japan is working to establish next-generation surgical medical facilities. Guided by our vision of being ‘more than just a hospital builder,’ we are excited to collaborate with SDP Japan in building systems that empower physicians to perform at their best and ensure that patients receive the optimal treatment they need.

Join Our Mission

To accelerate the expansion of our partner medical institutions, we are hiring in the following areas:

• Patient marketing (digital and offline)
• Business development (medical supply procurement, physician support, turnaround initiatives)
• On-site operations (including secondments, roles for experienced medical office managers)

Visit our recruitment page for more information (Japanese only):
https://www.sdp-japan.com/recruit/info/

Company Profile

• Company Name: SDP Japan, Inc.
• Headquarters: Shibuya Dogenzaka Tokyu Building 6F, 1-10-8 Dogenzaka, Shibuya-ku, Tokyo
• Founded: January 14, 2014
• Website: https://www.sdp-japan.com/

Contacts

SDP Japan, Inc. – Public Relations
Tel: +81-3-6457-9303
Email: [email protected] 

SOURCE SDP Japan, Inc

MCKINNEY, Texas, June 13, 2025 — Cytracom, a leading provider of Secure Access Service Edge (SASE) and Unified Communications as a Service (UCaaS) solutions for Managed Service Providers (MSPs), today announced the acquisition of Tentacle, a modern platform that helps organizations manage cybersecurity assessments, monitor third-party risk, and operationalize Governance, Risk, and Compliance (GRC) programs.

This acquisition represents a significant advancement in Cytracom’s Security Risk Management (SRM) strategy and further aligns with the company’s mission to empower MSPs to grow beyond traditional IT services and embrace a more strategic advisory role, guiding their clients through the evolving discipline of risk management. With increased scrutiny from regulatory bodies and mounting pressure from cyber insurers, MSPs are being called upon to act as true Risk Advisors, helping clients meet compliance mandates and improve their overall security posture. The integration of Tentacle into the Cytracom platform delivers a robust response to this need, offering structured, repeatable, and collaborative tools that make it easier for MSPs to deliver value-added risk and compliance services.

Cytracom entered the SRM category through the acquisition of Telivy, introducing capabilities that enable MSPs to automate risk assessments, deliver recurring compliance documentation, and drive consultative engagements. Tentacle builds upon this foundation by allowing partners to centralize security program data, collaborate in real time with clients and third parties, and map internal practices to industry frameworks such as HIPAA, PCI, and FTC Safeguards. Its platform not only reduces the administrative burden of ongoing assessments but also provides the structure needed to move from one-time reviews to ongoing program management.

“MSPs are increasingly being asked to manage risk as much as they manage technology,” said Zane Conkle, CEO of Cytracom. “This shift creates both a challenge and an opportunity. With the acquisition of Tentacle, we’re giving our partners the platform they need to step into this evolving role with confidence—helping clients navigate compliance, track progress over time, and build programs that stand up to external scrutiny, while also enabling MSPs to clearly demonstrate the ongoing value of their services.”

The rising demand for compliance-focused services is one of the most urgent trends in the MSP channel. SMB clients now face requirements driven by regulatory frameworks, industry-specific mandates, and cyber insurance audits. Tentacle’s ability to organize and share assessment data, manage third-party relationships, and ensure audit readiness positions it as a key component of Cytracom’s vision to simplify and scale SRM and GRC management for the channel.

“This is another step forward in building a complete platform that empowers MSPs to connect the modern workforce—securely, reliably, and within the evolving frameworks of GRC,” said John Tippett, Chief Commercial Officer. “Whether it’s unified communications, secure access, or risk management, our focus remains on making these capabilities accessible, intuitive, and impactful for the partners who deliver them every day.”

By integrating Tentacle into its broader infrastructure software platform, Cytracom continues to deepen its investment in the tools MSPs need to succeed in a risk- and compliance-driven world.

“We’ve been investing heavily in Telivy as a platform for recurring cybersecurity assessments and compliance workflows,” added Rob McDonald, Chief Product Officer at Cytracom. “Bringing in Tentacle’s proven technology allows us to combine their robust architecture with our existing development strategy, resulting in a dramatic acceleration of what we can bring to market. It significantly advances our mission to give MSPs scalable, differentiated tools for security and compliance.”

With solutions spanning VoIP, SASE, and SRM, Cytracom continues to equip partners to deliver critical infrastructure that is secure, scalable, and compliant—all from a single, unified platform built exclusively for the MSP channel.

About Cytracom

Cytracom, a Sverica Capital Management portfolio company, provides critical infrastructure technologies for businesses, delivering cloud-based unified communications and secure networking solutions tailored for managed service providers (MSPs) and small to medium-sized businesses (SMBs). By simplifying complex technologies, Cytracom ensures that businesses remain connected, secure, and resilient in an ever-evolving digital landscape. Our solutions, including SRM, GRC, UCaaS, and SASE platforms, are designed to empower businesses with the essential technologies they need to thrive. Headquartered in McKinney, Texas, Cytracom supports partners and customers across North America. To learn more, visit cytracom.com.

Media Contact: Dana Liedholm | [email protected]

SOURCE Cytracom